Fig. 5From: Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancerNew Metastasis-free Survival. The new metastasis-free survival with experimental therapy was 9.2 months (95% CI: 5.1 to 14.8). New metastasis-free survival was defined as the time from randomization to death or disease progression due to a new metastasisBack to article page